Immunodeficient Mice

IMMUNODEFICIENT MICE

NCG-hIL15

Strain Name: NOD/ShiLtJGpt-Prkdcem26Cd52Il2rgem26Cd22Il15em1Cin(hIL15)/Gpt
Strain Type: Knock-in
Strain Number: T004886
Background Strain: NCG

STRAIN DESCRIPTION

The NCG-hIL15 mouse is an enhanced version of the NCG strain with a humanized IL-15 gene knock-in. IL-15 is a pleiotropic cytokine produced by various cells such as activated monocytes/macrophages, epidermal cells, and fibroblasts, exhibiting biological activity similar to IL-2. It plays a critical role in activating and supporting the proliferation and survival of T cells, B cells, and NK cells. The expression of human IL-15 in NCG-hIL15 mice improve the the function and persistence of human NK cells, making this strain especially valuable for immuno-oncology research and reconstitution of the human immune system. Additionally, NCG-hIL15 can be combined with other humanized cytokine strains to create advanced humanized models.

APPLICATIONS

NK cell development

Tumor immunotherapy in which NK cells or NK and T cells act in combination

NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC)

Efficacy validation of CAR-NK

Human hematopoietic and immune system research

BASIC INFORMATION

Strain Name

NOD/ShiLtJGpt-Prkdcem26Cd52Il2rgem26Cd22Il15em1Cin(hIL15)/Gpt

Strain Number

T004886

Official Symbol

Il15

Official Full Name

interleukin 15

Also Known As

AI503618,IL-15

NCBI Number

Strain Background

[N000235] NOD/ShiLtJGpt

Modification Type

Knock in (KI)

Inventory Status

Live Animal, Cryopreserved

Health Status

Specific pathogen free (SPF)

Publications

1.Treating a type 2 diabetic patient with impaired pancreatic islet function by personalized endoderm stem cell-derived islet tissue. Cell Discov (2024)

2.Orchestrating NK and T cells via tri-specific nano-antibodies for synergistic antitumor immunity. Nat Commun (2024)

3.Dipeptide PA3264 derived from rare and endangered Squama Manis is a novel bioactive peptide for the treatment of triple-negative breast cancer. Chin Med (2024)